GO:1904386 response to L-phenylalanine derivative: Metabolic Signaling, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904386 (response to L-phenylalanine derivative) is a biological process describing any change in cell or organism state caused by an L-phenylalanine derivative stimulus.
• L-phenylalanine derivatives include the amino acid itself, its metabolic products, and synthetic analogs such as nateglinide and carotegrast methyl.
• The process is central to phenylketonuria (PKU) research, where sapropterin and sepiapterin act as L-phenylalanine-lowering agents.
• Key molecular players include phenylalanine hydroxylase (PAH), the insulin secretagogues, and metal-ion-chelating phenylalanine nanostructures.
• Experimental models range from CRISPR knockout of PAH to knock-in of patient mutations and overexpression of BH4 synthesis enzymes.
• Studying this term helps link amino acid sensing to immune modulation, metabolic disease, and cancer therapy.
Description
GO:1904386, response to L-phenylalanine derivative, is a Gene Ontology biological process that captures how cells and organisms react to a stimulus from any L-phenylalanine derivative. L-phenylalanine is an essential aromatic amino acid, and its derivatives include metabolic intermediates, pharmacological agents, and synthetic analogs that can trigger measurable changes in movement, secretion, enzyme production, or gene expression. This term is therefore relevant to researchers in metabolism, neuroscience, and pharmacology who need to annotate and interpret experiments involving phenylalanine-related compounds.
response to L-phenylalanine derivative At A Glance
| GO ID | GO:1904386 |
|---|---|
| GO term | response to L-phenylalanine derivative |
| Ontology | biological_process |
| Synonym | none |
| Major function | Cellular and organismal response to L-phenylalanine derivatives, including metabolic, signaling, and gene expression changes |
| Related diseases | Phenylketonuria, diabetes, cancer, immune dysfunction |
| Key genes | PAH, GCH1, SPR, SLC7A5, SLC3A2, INS, GCG, GLP1R, etc. |
| Research methods | CRISPR knockout, knock-in, overexpression, metabolomics, immune assays |
What Is GO:1904386?
According to the QuickGO definition, GO:1904386 refers to any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an L-phenylalanine derivative stimulus. In other words, it is the collection of cellular and physiological responses triggered when a cell encounters an L-phenylalanine derivative, whether that derivative is a natural metabolite, a drug, or a synthetic molecule.
Why Is response to L-phenylalanine derivative Important in Cell Biology?
Understanding GO:1904386 is important because L-phenylalanine derivatives are not only metabolic intermediates but also therapeutic agents and disease biomarkers. For example, sapropterin and sepiapterin are used to lower blood phenylalanine in phenylketonuria, and their effects are mediated through responses captured by this term. Nateglinide, an insulin secretagogue, is a derivative of phenylalanine that triggers rapid insulin release, linking this process to diabetes research. Moreover, metal-ion-chelating phenylalanine nanostructures can reverse immune dysfunction and sensitize breast tumors to immune checkpoint blockade, showing that responses to L-phenylalanine derivatives have broad biomedical implications.
• Phenylketonuria: L-phenylalanine derivatives such as sapropterin and sepiapterin are used to manage blood phenylalanine levels.
• Diabetes: Nateglinide, a phenylalanine derivative, stimulates insulin secretion and is used to treat type 2 diabetes.
• Cancer immunotherapy: Phenylalanine nanostructures can reverse immune dysfunction and enhance checkpoint blockade efficacy.
• Inflammatory bowel disease: Carotegrast methyl, an L-phenylalanine derivative, is approved for ulcerative colitis.
• Neurotransmission: Phenylalanine derivatives can affect neurotransmitter synthesis and signaling.
• Metabolic engineering: Responses to L-phenylalanine derivatives are relevant for microbial and plant metabolic engineering.
• Drug development: Many phenylalanine-based drugs require understanding of this response for efficacy and safety.
• Gene regulation: L-phenylalanine derivatives can alter gene expression programs, including those involved in amino acid transport and metabolism.
• Immune modulation: Phenylalanine derivatives can influence immune cell function and tumor microenvironment.
• Personalized medicine: Genetic variants in PAH and related genes affect individual responses to L-phenylalanine derivatives.
What Happens During response to L-phenylalanine derivative?
Stimulus recognition and transport
In simple terms: The cell first needs to sense and take up the L-phenylalanine derivative.
L-phenylalanine derivatives can enter cells via amino acid transporters such as SLC7A5/SLC3A2 (LAT1) or interact with cell-surface receptors. This step determines the intracellular concentration and availability of the stimulus. For example, nateglinide, a phenylalanine derivative, acts on pancreatic beta cells by closing ATP-sensitive potassium channels, but its transport and local concentration are critical for its insulinotropic effect. Similarly, sapropterin, a synthetic tetrahydrobiopterin, is a derivative that acts as a cofactor for phenylalanine hydroxylase, and its cellular uptake is essential for lowering phenylalanine.
Metabolic conversion and cofactor interactions
In simple terms: Once inside, the derivative can be converted or can interact with enzymes that need it as a cofactor.
L-phenylalanine is primarily metabolized by phenylalanine hydroxylase (PAH) to tyrosine, a reaction that requires tetrahydrobiopterin (BH4) as a cofactor. Derivatives such as sapropterin and sepiapterin are used to enhance BH4 availability, thereby increasing PAH activity and reducing phenylalanine levels. In parallel, other derivatives like nateglinide do not serve as cofactors but modulate ion channels and signaling pathways.
Signal transduction and gene expression changes
In simple terms: The derivative triggers signals that change which genes are turned on or off.
Binding or metabolism of L-phenylalanine derivatives can activate signaling cascades, including mTOR and insulin signaling, leading to changes in gene expression. For instance, nateglinide stimulates insulin secretion by increasing intracellular calcium and activating transcription factors that regulate insulin gene expression. In immune cells, phenylalanine nanostructures can modulate immune-related gene expression and cytokine production, reversing immune dysfunction.
Physiological and cellular responses
In simple terms: The ultimate outcome is a change in cell behavior, such as secretion, movement, or proliferation.
The integrated response can include increased insulin secretion from pancreatic beta cells, reduced blood phenylalanine in PKU patients, or enhanced antitumor immunity. For example, sepiapterin treatment leads to lower blood phenylalanine in PKU models, while metal-ion-chelating phenylalanine nanostructures sensitize breast tumors to immune checkpoint blockade by reversing immune dysfunction. These responses are the measurable outputs of GO:1904386.
Key Genes Involved in GO:1904386 response to L-phenylalanine derivative
The following genes and proteins are central to the response to L-phenylalanine derivatives, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PAH | Converts phenylalanine to tyrosine using BH4 cofactor | Mutations cause PKU; target for sapropterin and sepiapterin |
| GCH1 | Rate-limiting enzyme in BH4 synthesis | Modulates BH4 levels; relevant to PKU and neurotransmitter synthesis |
| SPR | Recycles BH4 via sepiapterin reductase | Defects affect BH4 regeneration; target for sepiapterin |
| SLC7A5 | L-type amino acid transporter for phenylalanine | Mediates cellular uptake of phenylalanine derivatives |
| SLC3A2 | Chaperone for SLC7A5 | Required for LAT1 function; affects drug transport |
| INS | Insulin hormone | Nateglinide stimulates insulin secretion; diabetes research |
| GCG | Glucagon hormone | Counter-regulatory to insulin; affected by phenylalanine derivatives |
| GLP1R | GLP-1 receptor | Cross-talk with insulin secretagogues; diabetes |
| ABCC8 | Sulfonylurea receptor subunit of KATP channel | Target of nateglinide; regulates insulin release |
| KCNJ11 | Inward rectifier K+ channel subunit | Nateglinide binding closes channel; insulin secretion |
| CACNA1C | Voltage-gated calcium channel | Mediates calcium influx for insulin exocytosis |
| ITGB1 | Integrin beta-1 | Involved in phenylalanine nanostructure-mediated immune modulation |
| CD274 | PD-L1 immune checkpoint | Phenylalanine nanostructures sensitize tumors to checkpoint blockade |
| PDCD1 | PD-1 immune checkpoint | Target of immune checkpoint therapy; modulated by phenylalanine nanostructures |
| TNF | Tumor necrosis factor | Cytokine modulated by phenylalanine derivatives in immune cells |
| IL6 | Interleukin-6 | Inflammatory cytokine affected by phenylalanine nanostructures |
| NFKB1 | NF-kB transcription factor | Mediates inflammatory signaling in response to phenylalanine derivatives |
How Is response to L-phenylalanine derivative Regulated?
The response to L-phenylalanine derivatives is regulated at multiple levels. At the metabolic level, PAH activity is controlled by BH4 availability, which is synthesized by GCH1 and recycled by SPR. At the signaling level, insulin secretagogues like nateglinide regulate KATP channels and calcium influx, which are modulated by glucose and hormonal signals. In immune cells, phenylalanine nanostructures can regulate NF-kB and cytokine production, influencing the tumor microenvironment. Additionally, amino acid transporters such as SLC7A5/SLC3A2 are regulated by amino acid availability and stress signals, affecting intracellular concentrations of phenylalanine derivatives.
response to L-phenylalanine derivative and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PAH | Phenylketonuria | CRISPR knockout of PAH in HepG2 cells; knock-in of common PKU mutations |
| GCH1 | BH4 deficiency, PKU | Overexpression of GCH1 to increase BH4; knockout to model deficiency |
| KCNJ11 | Neonatal diabetes, type 2 diabetes | Point mutation knock-in of KCNJ11 variants; patch-clamp studies |
| ABCC8 | Hyperinsulinism, diabetes | Knockout of ABCC8 in beta cells; insulin secretion assays |
| CD274 | Cancer immunotherapy | Overexpression of PD-L1 in breast cancer cells; immune co-culture |
Phenylketonuria (PKU)
PKU is caused by mutations in PAH, leading to toxic accumulation of phenylalanine. L-phenylalanine derivatives such as sapropterin and sepiapterin are used to lower blood phenylalanine by enhancing PAH activity or providing BH4. Understanding GO:1904386 helps in designing therapies that target this response.
Diabetes mellitus
Nateglinide, a phenylalanine derivative, stimulates insulin secretion by closing KATP channels in pancreatic beta cells. This response is critical for managing postprandial hyperglycemia in type 2 diabetes. Research on GO:1904386 can inform the development of better insulin secretagogues.
Cancer and immune dysfunction
Metal-ion-chelating phenylalanine nanostructures can reverse immune dysfunction and sensitize breast tumors to immune checkpoint blockade. This response involves modulation of immune checkpoint proteins and cytokines, highlighting the role of L-phenylalanine derivatives in cancer immunotherapy.
Inflammatory bowel disease
Carotegrast methyl, an L-phenylalanine derivative, is approved for ulcerative colitis. Its mechanism involves blocking alpha-4 integrins, but the response to this derivative is part of GO:1904386.
From response to L-phenylalanine derivative-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PAH knockout alter response to sapropterin? | PAH knockout HepG2 cells; sapropterin treatment |
| Does a specific PAH mutation affect BH4 responsiveness? | Point mutation knock-in of PAH variants in patient iPSCs |
| Can overexpression of GCH1 increase BH4 and lower phenylalanine? | GCH1 overexpression in hepatocytes |
| Does nateglinide require KCNJ11 for insulin secretion? | KCNJ11 knockout pancreatic beta cells; nateglinide treatment |
| Do phenylalanine nanostructures enhance checkpoint blockade? | Knock-in of PD-L1 reporter in breast cancer cells; immune co-culture |
| What genes are differentially expressed upon L-phenylalanine derivative treatment? | CRISPR library screening with phenylalanine derivatives |
How to Study the response to L-phenylalanine derivative Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Metabolomics | Levels of phenylalanine and derivatives | PKU diagnosis and treatment monitoring |
| RNA-seq | Gene expression changes | Identifying pathways activated by L-phenylalanine derivatives |
| CRISPR knockout screen | Genes required for response | Discovering novel regulators of insulin secretion or immune modulation |
| Patch-clamp electrophysiology | Ion channel activity | Studying nateglinide effects on KATP channels |
| Calcium imaging | Intracellular calcium flux | Measuring beta cell activation by nateglinide |
| Immune cell co-culture | T cell activation and cytokine release | Testing phenylalanine nanostructures for immunotherapy |
| Western blot | Protein expression and phosphorylation | Assessing PAH or signaling proteins |
| ELISA | Cytokine or insulin secretion | Quantifying functional responses |
Metabolomics and amino acid profiling
Metabolomics can quantify phenylalanine and its derivatives in cells and body fluids. This method is essential for studying the response to L-phenylalanine derivatives, such as measuring blood phenylalanine in PKU models treated with sapropterin.
CRISPR screening and functional genomics
CRISPR knockout libraries can identify genes required for the response to L-phenylalanine derivatives. For example, a genome-wide screen could reveal novel regulators of nateglinide-induced insulin secretion or phenylalanine nanostructure-mediated immune modulation.
Transcriptomics and RNA-seq
RNA-seq measures gene expression changes following treatment with L-phenylalanine derivatives. This can uncover signaling pathways and transcription factors activated by these compounds, such as NF-kB in immune cells.
Imaging and cell-based assays
Live-cell imaging can track calcium influx, insulin granule exocytosis, or immune cell activation in response to L-phenylalanine derivatives. These assays provide functional readouts of GO:1904386.
How CRISPR Can Be Used to Study GO:1904386 response to L-phenylalanine derivative
Knockout
CRISPR knockout of genes such as PAH, GCH1, or KCNJ11 can model loss-of-function states and test their requirement for the response to L-phenylalanine derivatives. For example, PAH knockout cells fail to metabolize phenylalanine and can be used to test sapropterin efficacy.
Point Mutation
Introducing specific point mutations (e.g., in PAH or KCNJ11) via CRISPR base editing or HDR can mimic patient variants and assess their impact on drug response. This is crucial for personalized medicine in PKU and diabetes.
Knock-in
Knock-in of reporter genes or tagged alleles (e.g., PD-L1 reporter) allows real-time monitoring of responses to L-phenylalanine derivatives in live cells. This can be used to screen for drugs that modulate immune checkpoint expression.
Overexpression
CRISPR activation or cDNA overexpression can increase levels of genes like GCH1 or SLC7A5 to study their role in enhancing or dampening the response to L-phenylalanine derivatives. Overexpression of GCH1 may boost BH4 and improve phenylalanine clearance.
How EDITGENE Supports response to L-phenylalanine derivative Research
Researchers studying response to L-phenylalanine derivative-related genes often need to determine whether a candidate gene is causally involved in the cellular response to these compounds. EDITGENE provides a comprehensive suite of CRISPR services to enable such functional studies, from knockout to precise point mutations and overexpression.
Contact EDITGENE today to design your custom CRISPR model for response to L-phenylalanine derivative research.
Frequently Asked Questions About response to L-phenylalanine derivative
What is GO:1904386?
GO:1904386 is a Gene Ontology biological process term for any process that results in a change in state or activity of a cell or organism as a result of an L-phenylalanine derivative stimulus.
What are L-phenylalanine derivatives?
L-phenylalanine derivatives include the amino acid L-phenylalanine, its metabolic products, and synthetic analogs such as nateglinide, sapropterin, sepiapterin, and carotegrast methyl.
What genes are involved in response to L-phenylalanine derivative?
Key genes include PAH, GCH1, SPR, SLC7A5, SLC3A2, INS, GCG, KCNJ11, ABCC8, and immune-related genes like CD274 and PDCD1.
How is response to L-phenylalanine derivative studied?
It is studied using metabolomics, RNA-seq, CRISPR screens, patch-clamp, calcium imaging, and immune assays.
What diseases are linked to response to L-phenylalanine derivative?
Phenylketonuria, diabetes mellitus, inflammatory bowel disease, and cancer immunotherapy are linked to this process.
What is the role of PAH in response to L-phenylalanine derivative?
PAH converts L-phenylalanine to tyrosine using BH4 as a cofactor; mutations cause PKU and affect response to sapropterin.
How does nateglinide relate to GO:1904386?
Nateglinide is an L-phenylalanine derivative that stimulates insulin secretion by closing KATP channels in beta cells, representing a response to an L-phenylalanine derivative.
Can CRISPR be used to study response to L-phenylalanine derivative?
Yes, CRISPR knockout, knock-in, point mutation, and overexpression models are used to study genes involved in this response.
What is the connection between L-phenylalanine derivatives and cancer?
Metal-ion-chelating phenylalanine nanostructures can reverse immune dysfunction and sensitize breast tumors to immune checkpoint blockade.
What are the therapeutic implications of GO:1904386?
Therapies like sapropterin for PKU, nateglinide for diabetes, and carotegrast methyl for ulcerative colitis target or involve this response.
Conclusion
GO:1904386 (response to L-phenylalanine derivative) is a biologically and clinically significant process that spans metabolic, signaling, and immune responses. From phenylketonuria to diabetes and cancer immunotherapy, L-phenylalanine derivatives play diverse roles, and understanding the underlying mechanisms can lead to new therapeutic strategies. Researchers can leverage CRISPR models and multi-omics approaches to dissect this process further.
References
- 1. Williams RA et al.. 2025. Sepiapterin for the treatment of phenylketonuria.. Expert Opin Pharmacother 26(8):933-938 PMID: 40272408
- 2. Yu B et al.. 2025. De novo design of light-responsive protein-protein interactions enables reversible formation of protein assemblies.. Nat Chem 17(12):1910-1919 PMID: 40877575
- 3. Dunn CJ et al.. 2000. Nateglinide.. Drugs 60(3):607-615; discussion 616-7 PMID: 11030470
- 5. Dhillon S. 2022. Carotegrast Methyl: First Approval.. Drugs 82(9):1011-1016 PMID: 35723803
- 6. Tan M et al.. 2024. Metal-ion-chelating phenylalanine nanostructures reverse immune dysfunction and sensitize breast tumour to immune checkpoint blockade.. Nat Nanotechnol 19(12):1903-1913 PMID: 39187583
- 7. Somaraju UR et al.. 2015. Sapropterin dihydrochloride for phenylketonuria.. Cochrane Database Syst Rev 2015(3):CD008005 PMID: 25812600
- 8. Davies MJ. 2002. Insulin secretagogues.. Curr Med Res Opin 18 Suppl 1:s22-30 PMID: 12365816
